Recolony Insights

Recolony is a spin-off company from the University of Zurich that started as a research project in the Department of Gastroenterology and Hepatology at the University Hospital Zurich. The investigation of the effect of certain commensal bacteria on the anti-cancer immune response led to impressive results and to the decision to translate these findings to a clinical application. With this mission, Recolony became part of the Wyss Zurich Translational Center, a joint accelerator of the University of Zurich and ETH Zurich. 

 

Our incentive is to provide high-quality therapy to cancer patients, with the aim to maximize treatment efficacy and at the same time the quality of life of the people suffering from this life-changing disease. For that purpose, we invest our efforts in high-class research to produce new, innovative therapies that ultimately bring the desired benefits to the patients.

Recolony team.jpg

The Leadership Team

The core colony

The Advisory Board

The support colony

Together we succeed

Interested in collaborating?